D4S.F Daiichi Sankyo Company Limited

Healthcare Pharmaceuticals Frankfurt Exchange
15.40 EUR
Close of Nov 12, 2026
12.96 20.88
Market cap
EUR 28.1B
P/E
18.3x
P/B
2.86x
ROE
17.2%
Dividend yield
3.62%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.

Is D4S.F undervalued?

Graham number
Price15.40
Graham value10.08
Premium52.7%

D4S.F trades 52.7% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Daiichi Sankyo Company Limited fundamental analysis

No fundamental analysis for Daiichi Sankyo Company Limited yet.

Daiichi Sankyo Company Limited stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Daiichi Sankyo Company Limited

Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan and internationally. The company offers Enhertu for the treatment of HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule for colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3, as well as symptomatic TGCT; Vanfly…

Full company profile